Drugs in preclinical to phase II clinical development for the treatment of erectile dysfunction.

Abstract:

INTRODUCTION:Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical placement of a penile prosthesis - the final step in the management of treatment-refractory ED. Areas covered: This review examines innovative treatments such as alternative vasoactive agents, trophic factors and bio-compounds as well as gene and stem cell therapy. All therapies are currently in some phase of development for the management of ED. Using the MedLine and FDA Clinical Trials Registry, recent developments in treatment of ED were queried. Expert opinion: Recent studies have demonstrated the potential for multiple, novel therapies in the treatment of ED. Much of the work requires further experimentation in large-scale, blinded, placebo-controlled studies. This will require a concerted effort to bring these products to market.

authors

Smith-Harrison L,Starke NR,Smith RP,Kovac JR

doi

10.1080/13543784.2017.1324570

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

669-675

issue

6

eissn

1354-3784

issn

1744-7658

journal_volume

26

pub_type

杂志文章,评审
  • Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.

    abstract:INTRODUCTION:the search for effective inhibitors to multiple infectious agents including influenza, smallpox and hemorrhagic fever viruses is an area of active research as many of these agents pose dramatic health and economic challenges to the human population. Many of these infectious agents are not only endemic thre...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.547852

    authors: Narayanan A,Bailey C,Kashanchi F,Kehn-Hall K

    更新日期:2011-02-01 00:00:00

  • Novel inhibitors of the early steps of the HIV-1 life cycle.

    abstract::Considerable advances have been made on compounds that are active as inhibitors of HIV entry and fusion. The discovery of chemokines a few years ago focused the attention on coreceptor inhibitors in addition to fusion and attachment blockers. During the last 5 years, there has been an intense research activity from bo...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.1.11

    authors: Citterio P,Rusconi S

    更新日期:2007-01-01 00:00:00

  • Zolmitriptan: a new acute treatment for migraine.

    abstract::Zolmitriptan is a new oral acute treatment for migraine. It is a selective and potent agonist at the serotonin (5-HT)(1B/1D) receptor and was developed to improve on the oral bioavailability, tissue selectivity and CNS penetration of earlier compounds. Animal studies confirmed that these objectives had been attained. ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.4.633

    authors: Rolan PE,Martin GR

    更新日期:1998-04-01 00:00:00

  • Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis.

    abstract::Diminished efficacy in terms of clinical relapses and lesion load on magnetic resonance images for patients developing neutralising antibodies (NAbs) to recombinant IFN-beta may be found in multiple sclerosis. NAbs become detectable over the first few years of therapy, disappearing during the treatment course in some ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.7.1153

    authors: Bagnato F,Pozzilli C

    更新日期:2003-07-01 00:00:00

  • The therapeutic potential of CRF1 antagonists for anxiety.

    abstract::Preclinical studies suggest that the brain corticotropin-releasing factor (CRF) systems mediate anxiety-like behavioural and somatic responses through actions at the CRF1 receptor. CRF1 antagonists block the anxiogenic-like effects of CRF and stress in animal models. Cerebrospinal fluid levels of CRF are elevated in s...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.7.799

    authors: Zorrilla EP,Koob GF

    更新日期:2004-07-01 00:00:00

  • Discontinued drug therapies to treat diabetes in 2014.

    abstract:INTRODUCTION:Available drugs partially attenuate the hyperglycemia characteristic of diabetes. However, successful approaches to treat the root cause or to cure or prevent diabetes remain elusive. Drug discovery and development programs continue to focus on mechanisms that impact specific symptoms of diabetes. In 2014,...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.2015.1058777

    authors: Colca JR

    更新日期:2015-01-01 00:00:00

  • Recent advances in natriuretic peptides in congestive heart failure.

    abstract::Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exog...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.6.643

    authors: Boerrigter G,Burnett JC Jr

    更新日期:2004-06-01 00:00:00

  • Investigations on gossypol: past and present developments.

    abstract::Gossypol has received significant attention as a result of its potential therapeutic application as a male antifertility agent. Furthermore, recent research examining the biological activity of gossypol has revealed a number of other promising lines of enquiry. These have focused on the antitumour, antiviral and antio...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.11.1419

    authors: Dodou K,Anderson RJ,Small DA,Groundwater PW

    更新日期:2005-11-01 00:00:00

  • Investigational drugs for coagulation disorders.

    abstract:INTRODUCTION:The current standard treatment in persons with hemophilia (PWH) is prophylaxis, given intravenously twice or thrice weekly, which is associated with a non negligible burden on patients' quality of life. Therefore the main attempts aiming to improve the management of PWH are targeted towards the development...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.798302

    authors: Mannucci PM,Mancuso ME

    更新日期:2013-08-01 00:00:00

  • Endothelin receptor antagonists in cardiology clinical trials.

    abstract::Endothelin-1 (ET-1) is enhanced and has been demonstrated to be a prognostic marker in patients with advanced stages of heart failure, acute ischaemic syndromes, myocardial infarction and pulmonary hypertension. Activation of the endothelin (ET) system is associated with adverse haemodynamic consequences in patients w...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.3.431

    authors: Neunteufl T,Berger R,Pacher R

    更新日期:2002-03-01 00:00:00

  • Cardiac fibrosis: emerging agents in preclinical and clinical development.

    abstract:INTRODUCTION:Myocardial fibrosis is a remarkably dynamic process mediated by different molecular pathways that represent potential targets of novel therapeutic interventions. Transforming Growth Factor-beta (TGF-β), connective Tissue Growth Factor (cTGF) and Galectin-3 (Gal-3) represent the most promising targets on wh...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2021.1868432

    authors: Spoladore R,Falasconi G,Fiore G,Di Maio S,Preda A,Slavich M,Margonato A,Fragasso G

    更新日期:2021-01-04 00:00:00

  • Developments in the treatment of chronic hepatitis C.

    abstract::Hepatitis C virus is the most common chronic, blood-bourne infection, affecting 170 million people worldwide, approximately 3% of the global population. Of those infected with hepatitis C virus, 50 - 85% will develop chronic hepatitis C. Although hepatitis C is primarily a disease of the liver, a diagnosis is currentl...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.4.515

    authors: Pockros PJ

    更新日期:2002-04-01 00:00:00

  • Dasatinib : a novel therapy for breast cancer?

    abstract:INTRODUCTION:Dasatinib is a novel tyrosine kinase inhibitor with activity against the Src family kinases. The Src pathway is active in breast cancer and has been shown to promote cell proliferation, invasiveness, and metastases. Preclinical data support the use of dasatinib to inhibit breast cancer cell growth, modulat...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.2013.793308

    authors: Scher KS,Somlo G

    更新日期:2013-06-01 00:00:00

  • Ixabepilone for the treatment of solid tumors: a review of clinical data.

    abstract:BACKGROUND:Microtubule stabilizing agents such as taxanes are an integral part of therapy for multiple solid tumors. However, due to limitations of these agents, newer more effective cytotoxic agents are necessary. Ixabepilone, an epothilone B analog, is a novel microtubule stabilizing agent. OBJECTIVE:This review pro...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.3.423

    authors: Denduluri N,Swain SM

    更新日期:2008-03-01 00:00:00

  • AIT-082, a novel purine derivative with neuroregenerative properties.

    abstract::Preclinical and clinical evidence support the effectiveness of neurotrophins in Alzheimer's disease (AD) and neurodegenerative diseases. Delivery of neurotrophins to target sites in the brain remains a major obstacle for their use in humans. Development of orally active agents that mimic the effects of nerve growth fa...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.10.1413

    authors: Glasky AJ,Glasky MS,Ritzmann RF,Rathbone MP

    更新日期:1997-10-01 00:00:00

  • Toll-like receptor modulation in cardiovascular disease: a target for intervention?

    abstract::Toll-like receptors (TLRs) form a family of pattern recognition receptors that have emerged as key mediators of innate immunity. These receptors sense invading microbes and initiate the immune response. TLR-mediated inflammation is an important pathogenic link between innate immunity and a diverse panel of clinical di...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.8.857

    authors: Földes G,von Haehling S,Anker SD

    更新日期:2006-08-01 00:00:00

  • Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.

    abstract:INTRODUCTION:Pro-protein [corrected] convertase subtilisin kexin (PCSK)-9 is a newly discovered protein involved in intracellular and extracellular regulation of low-density lipoprotein receptor (LDLR) expression. Autosomal dominant activating mutations in PCSK-9 cause familial hypercholesterolaemia whereas inactivatin...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.679340

    authors: Wierzbicki AS,Hardman TC,Viljoen A

    更新日期:2012-05-01 00:00:00

  • Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice.

    abstract::Proliferative diabetic retinopathy (PDR) demands both more effective and less expensive biologically based treatments. Our understanding of the pathophysiology of the disease is increasing as new biochemical pathways are identified. Most reports emphasize proangiogenic stimuli, with the natural inhibitory elements rec...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.8.1209

    authors: Hernández C,Simó R

    更新日期:2007-08-01 00:00:00

  • The role of telavancin in the treatment of MRSA infections in hospital.

    abstract:BACKGROUND:Serious infections caused by Gram-positive bacteria, particularly multi-drug resistant, are an important cause of morbidity and mortality in patients admitted to intensive care units. Thus, new antibiotics covering these pathogens are urgently needed. OBJECTIVE:To review characteristics of telavancin, a nov...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902845630

    authors: Bassetti M,Mikulska M,Righi E,Nicolini L,Viscoli C

    更新日期:2009-04-01 00:00:00

  • Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.

    abstract:IMPORTANCE OF THE FIELD:Aspirin, an irreversible inhibitor of thromboxane A(2) production, in combination with clopidogrel, an inhibitor of PY(12) ADP platelet receptors, represents the current standard-of-care of antiplatelet therapy for patients with acute coronary syndrome and those undergoing percutaneous coronary ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.521741

    authors: Tomasello SD,Angiolillo DJ,Goto S

    更新日期:2010-12-01 00:00:00

  • Metastatic melanoma: therapeutic agents in preclinical and early clinical development.

    abstract::Introduction: Advanced melanoma historically had a very poor outcome but targeted therapies and immune checkpoint inhibitors (IC) have changed the course of the disease and made durable responses possible. However, most patients will develop progressive disease, so further strategies to overcome treatment resistance a...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2020.1769066

    authors: Boos LA,Leslie I,Larkin J

    更新日期:2020-07-01 00:00:00

  • Non-invasive imaging of plaque vulnerability: an important tool for the assessment of agents to stabilise atherosclerotic plaques.

    abstract::Disruption of a vulnerable atherosclerotic plaque is well-recognised as the primary cause of stroke, non-fatal myocardial infarction and sudden cardiac death. Novel therapeutic agents are being developed to stabilise such plaques. The initial evaluation of these drugs would be facilitated by the use of non-invasive im...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.5.693

    authors: Sosnovik DE,Muller JE,Kathiresan S,Brady TJ

    更新日期:2002-05-01 00:00:00

  • Targeting tyrosine-kinases in ovarian cancer.

    abstract:INTRODUCTION:Epithelial ovarian cancer (EOC) is the leading cause of gynaecologic cancer death. Although in some cases initial treatment is effective, most of the women diagnosed with EOC will probably need medical treatment for their disease. There is a critical need to develop effective new strategies for the managem...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.816282

    authors: Morotti M,Becker CM,Menada MV,Ferrero S

    更新日期:2013-10-01 00:00:00

  • Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers.

    abstract::Introduction: Neuropathic pain is a chronic condition that significantly affects the quality of life of millions of people globally. Most of the pharmacologic treatments currently in use demonstrate modest efficacy and over half of all patients do not respond to medical management. Hence, there is a need for new, effi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2020.1728254

    authors: Kushnarev M,Pirvulescu IP,Candido KD,Knezevic NN

    更新日期:2020-03-01 00:00:00

  • Histopathological prognostic factors in early breast carcinoma: an evaluation of cell proliferation in carcinoma cells.

    abstract::Early breast carcinoma is defined as pathological stage 1 (pT1N0M0) tumour and its incidence has recently increased possibly due to the advent of mammography based mass screening. Overall survival of these patients is in general excellent, but more than 20% of them will eventually develop distant metastasis and die. T...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543781003718833

    authors: Sasano H

    更新日期:2010-04-01 00:00:00

  • Current and emerging investigational medical therapies for the treatment of overactive bladder.

    abstract::Overactive bladder (OAB) is a chronic distressing condition characterised by urinary urgency with or without urge incontinence, usually with frequency (voiding at least eight times daily) and nocturia. It affects millions of people worldwide independent of age, sex and race. The prevalence increases with age and is re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.9.1017

    authors: Tiwari A,Naruganahalli KS

    更新日期:2006-09-01 00:00:00

  • Novel therapeutic strategies targeting vascular endothelium in essential hypertension.

    abstract:IMPORTANCE OF THE FIELD:Several studies have demonstrated the high prevalence of hypertension and the crucial role of the association between endothelial function and hypertension. Thus, in depth investigation of the pathophysiological mechanisms linking endothelial dysfunction and hypertension, as well as evaluation o...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.522989

    authors: Tousoulis D,Papageorgiou N,Androulakis E,Paroutoglou K,Stefanadis C

    更新日期:2010-11-01 00:00:00

  • Oral amphipathic peptides as therapeutic agents.

    abstract::Cholesterol can promote inflammation by its ability to stimulate the production of reactive oxygen species that result in the formation of pro-inflammatory oxidised phospholipids. High-density lipoproteins (HDLs) are part of the innate immune response and can be either pro- or anti-inflammatory independently of plasma...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.1.13

    authors: Reddy ST,Anantharamaiah GM,Navab M,Hama S,Hough G,Grijalva V,Garber DW,Datta G,Fogelman AM

    更新日期:2006-01-01 00:00:00

  • Dronedarone: an amiodarone analogue.

    abstract::Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardia...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.4.415

    authors: Doggrell SA,Hancox JC

    更新日期:2004-04-01 00:00:00

  • Recent and ongoing clinical trials for treating colorectal cancer.

    abstract::Colorectal cancer is one of the most common cancers worldwide. Through well-designed clinical trials, advances have been made in the treatment of localised and advanced colorectal cancer. It has been established that 6 months of 5-fluorouracil-based chemotherapy will improve overall survival in patients with stage III...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.6.871

    authors: Mulcahy MF,Benson AB 3rd

    更新日期:2002-06-01 00:00:00